H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating and $120 price target on Cytokinetics (CYTK) after the company hosted an investor event to discuss new data related to aficamten that were presented at the European Society of Cardiology Congress, including primary results from the comparative Phase 3 MAPLE-HCM trial and longer-term efficacy and safety from the FORESTHCM extension study. Ahead of aficamten’s PDUFA date on December 26, the firm sees “little room left for doubt” and sees potential for the drug as “a next-in-class CMI for oHCM with a favorable label, as well as for additional label-expansion and quick adoption from future updated cardiomyopathy guidelines, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Receives Buy Rating from James Condulis Amid Promising Developments and Strategic Partnerships
- Cytokinetics price target raised to $96 from $87 at Stifel
- Cytokinetics rises 34.2%
- Cytokinetics price target raised to $84 from $77 at Citi
- Buy Rating for Cytokinetics: Aficamten Shows Promising Results in Hypertrophic Cardiomyopathy Trials